JP2013542914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542914A5 JP2013542914A5 JP2013519791A JP2013519791A JP2013542914A5 JP 2013542914 A5 JP2013542914 A5 JP 2013542914A5 JP 2013519791 A JP2013519791 A JP 2013519791A JP 2013519791 A JP2013519791 A JP 2013519791A JP 2013542914 A5 JP2013542914 A5 JP 2013542914A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 239000003446 ligand Substances 0.000 claims 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 210000002569 neuron Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 102000013498 tau Proteins Human genes 0.000 claims 3
- 108010026424 tau Proteins Proteins 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000009822 protein phosphorylation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36421010P | 2010-07-14 | 2010-07-14 | |
| US61/364,210 | 2010-07-14 | ||
| PCT/US2011/043866 WO2012009442A2 (en) | 2010-07-14 | 2011-07-13 | Anti-addl monoclonal antibody and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542914A JP2013542914A (ja) | 2013-11-28 |
| JP2013542914A5 true JP2013542914A5 (enExample) | 2014-08-28 |
| JP5934203B2 JP5934203B2 (ja) | 2016-06-15 |
Family
ID=45470057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519791A Active JP5934203B2 (ja) | 2010-07-14 | 2011-07-13 | 抗ａｄｄｌモノクローナル抗体およびこの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130115227A1 (enExample) |
| EP (1) | EP2593475B1 (enExample) |
| JP (1) | JP5934203B2 (enExample) |
| KR (1) | KR101842301B1 (enExample) |
| CN (1) | CN103140500B (enExample) |
| AU (1) | AU2011279221B2 (enExample) |
| BR (1) | BR112013000796B1 (enExample) |
| CA (1) | CA2805414C (enExample) |
| DK (1) | DK2593475T3 (enExample) |
| ES (1) | ES2573135T3 (enExample) |
| MX (1) | MX338640B (enExample) |
| RU (1) | RU2567808C2 (enExample) |
| WO (1) | WO2012009442A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| WO2013009703A2 (en) * | 2011-07-13 | 2013-01-17 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| HUE048722T2 (hu) * | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| ES2728578T3 (es) | 2013-09-20 | 2019-10-25 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores |
| US20190388519A1 (en) * | 2016-03-01 | 2019-12-26 | Macquarie University | Use of phosphorylated tau and p38gamma to treat a neurological condition |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| EP3999532A2 (en) * | 2019-07-16 | 2022-05-25 | Sanofi | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN116375857A (zh) * | 2023-03-30 | 2023-07-04 | 天津鸿宇泰生物科技有限公司 | 一种用于检测Tau蛋白的单链抗体及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4493825A (en) | 1982-10-05 | 1985-01-15 | Iowa State University Research Foundation | Purified and antigenically selective vaccines for domestic animals |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| CA2283557A1 (en) | 1997-03-10 | 1998-09-17 | Heather L. Davis | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant |
| RU2353389C2 (ru) * | 2002-10-09 | 2009-04-27 | Ринат Ньюросайенс Корп. | Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций |
| ES2246177B1 (es) * | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| AU2005269940A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
| AP2007003890A0 (en) * | 2004-07-30 | 2007-02-28 | Rinat Neuroscience Corp | Antibodies directed against amy-loid-beta peptide and methods using same |
| CA2790433A1 (en) * | 2004-10-25 | 2006-05-26 | Northwestern University | Anti-addl antibodies and uses thereof |
| JP5173426B2 (ja) * | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| JP5289963B2 (ja) * | 2005-10-21 | 2013-09-11 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗ａｄｄｌモノクローナル抗体およびその使用 |
-
2011
- 2011-07-13 AU AU2011279221A patent/AU2011279221B2/en active Active
- 2011-07-13 MX MX2013000490A patent/MX338640B/es active IP Right Grant
- 2011-07-13 ES ES11807457.4T patent/ES2573135T3/es active Active
- 2011-07-13 DK DK11807457.4T patent/DK2593475T3/en active
- 2011-07-13 US US13/809,475 patent/US20130115227A1/en not_active Abandoned
- 2011-07-13 KR KR1020137003618A patent/KR101842301B1/ko active Active
- 2011-07-13 JP JP2013519791A patent/JP5934203B2/ja active Active
- 2011-07-13 CA CA2805414A patent/CA2805414C/en active Active
- 2011-07-13 EP EP11807457.4A patent/EP2593475B1/en active Active
- 2011-07-13 RU RU2013106270/10A patent/RU2567808C2/ru active
- 2011-07-13 WO PCT/US2011/043866 patent/WO2012009442A2/en not_active Ceased
- 2011-07-13 CN CN201180034706.4A patent/CN103140500B/zh active Active
- 2011-07-13 BR BR112013000796-6A patent/BR112013000796B1/pt active IP Right Grant
-
2014
- 2014-07-09 US US14/326,974 patent/US9309309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542914A5 (enExample) | ||
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| JP7019198B2 (ja) | 補体関連疾患の予防及び治療のためのｃ５抗体及び方法 | |
| AU2019257379B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| JP6944375B2 (ja) | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 | |
| US20250051428A1 (en) | Antibodies to amyloid beta | |
| TWI551609B (zh) | 抗－顆粒溶解素抗體及其應用 | |
| JP2023120208A (ja) | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 | |
| JP2019108359A (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| JP7186266B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| AU2021258000A1 (en) | Antibody Molecules and Uses Thereof | |
| JP2020504759A (ja) | Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体 | |
| CA3004482A1 (en) | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto | |
| CN112805299B (zh) | 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查 | |
| EP3374381A1 (en) | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto | |
| AU2016353553A1 (en) | Amyloid beta epitopes and antibodies thereto | |
| US12286469B2 (en) | Humanized antibodies binding to amyloid-beta (A-beta) | |
| CA2856866C (en) | Administration of alpha4beta7 hetero-dimer-specific antibody | |
| JP2020524988A (ja) | 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用 | |
| CA3239286A1 (en) | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases | |
| EP3574020B1 (en) | Antibodies to amyloid beta | |
| CN108484765B (zh) | 一种抗人α-防御素-1单克隆抗体及其应用 | |
| WO2022081971A1 (en) | Notch4 antibodies and uses thereof | |
| EP2935324B1 (en) | Anti-staphylococcal antibodies | |
| US20250289877A1 (en) | Antibodies to Amyloid Beta |